Investigational Device Medicare Reimbursement Hinders New Coding
This article was originally published in The Gray Sheet
Executive Summary
Medical device manufacturers seeking a new code for Medicare reimbursement of a new commercial technology likely will have a more difficult time if they received payments for the device during clinical trials from the Health Care Financing Administration, observed Thomas Ault, a principal in the Washington, D.C.-based Health Policy Alternatives, Inc.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.